对医保药品“阴阳价”要一查到底

Core Viewpoint - The National Healthcare Security Administration has identified the illegal practice of "dual pricing" in designated retail pharmacies, where prices for insured patients are higher than for non-insured patients, prompting a call for stricter monitoring and enforcement against such practices [1][2][3] Group 1: Issues Identified - Some designated pharmacies are engaging in "dual pricing," which undermines the benefits of insurance for patients and damages the integrity of the healthcare fund [1] - The existence of "dual pricing" reflects a lack of transparency in drug pricing and distribution channels, allowing pharmacies to exploit information asymmetry [2] - The practice of "dual pricing" is a violation of laws and regulations, including the Price Law and Drug Administration Law, and contradicts the service agreements for designated pharmacies [2] Group 2: Recommendations for Action - Strict investigations and penalties should be implemented, including the use of big data and AI for monitoring pharmacy operations [3] - Penalties may include meetings with responsible parties, suspension of insurance settlements, and potential legal actions for severe violations [3] - Increased public awareness and education about patients' rights and reporting mechanisms should be promoted to encourage transparency and accountability in pharmacy operations [3]